Drug-induced pulmonary fibrosis

Saudi Medical Journal

Volumn 25, Issue 6, 2004, Pages 700-706

  Daba, Mohammed H ^a   El Tahir, Kamal E ^a   Al Arifi, Mohammed N ^a   Gubara, Othman A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ASBESTOS; BLEOMYCIN; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTOKINE; ENDOTHELIN 1; GOLD; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 8; METHOTREXATE; MITOMYCIN; MITOMYCIN C; NITROFURANTOIN; NUCLEAR FACTOR; OXYGEN RADICAL; PENICILLAMINE; PHOSPHOLIPASE; PLATELET DERIVED GROWTH FACTOR; PROCAINAMIDE; SILICON DIOXIDE; SOMATOMEDIN C; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

BACTERIAL INFECTION; CELL DAMAGE; CONNECTIVE TISSUE; COUGHING; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DYSPNEA; ENVIRONMENTAL EXPOSURE; ENZYME INHIBITION; FEVER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNE SYSTEM; LUNG ALVEOLUS CELL; LUNG FIBROSIS; LUNG FUNCTION TEST; LYMPHOCYTE; MACROPHAGE; MYCOSIS; REVIEW; RHEUMATOID ARTHRITIS; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY;

ANTIOXIDANTS; APOPTOSIS; CYTOKINES; HUMANS; PULMONARY FIBROSIS;

EID: 3042731982     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Cooper JA Jr. Drug induced lung disease. Adv Intern Med 1997; 42: 231-268.
2. Kuwano K, Hagimoto N, Hara N. Molecular mechanisms of pulmonary fibrosis and current treatment. Curr Mol Med 2001; 1: 551-573.
3. Reynolds HY. Diagnostic and management strategies for diffuse interstitial lung disease. Chest 1998; 113: 202.
4. Coker RK, Laurent GJ. Pulmonary fibrosis: Cytokines in the balance. Eur Respir J 1998; 11: 1218-1221.
5. Strieter RM. Mechanisms of pulmonary fibrosis: Conference summary. Chest 2001; 120: 77S-85S.
6. Ziesche R, Hofbaur E, Wittman K, Petkov V, Block LH. A preliminary study of long term treatment with interferon g-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-1269.
7. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin-4. J Clin Invest 1992; 90: 1479-1485.
8. Oriente A, Fedarco NS, Pacocha SE, Huang SK, Lichtenstein LM, Essaayan DM. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000; 292: 988-994.
9. Branton MH, Kopp JB. Tansforming growth factor-β and fibrosis. Microbes Infect 1999; 1: 1349-1365.
10. Cooper JA Jr. Pulmonary fibrosis: pathways are slowly coming into light. Am J Respir Cell Mol Biol 2000; 22: 520-523.
11. Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7: 431-436.
12. MacNee W, Rahman I. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 1995; 50: S53-S58.
13. Strausz J, Muller-Quernheim J, Steppling H, Ferlinze R. Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1990; 141: 124-128.
14. Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD. The accuracy of the clinical diagnosis of new onset idiopathic pulmonary fibrosis and other interstitial lung diseases: A prospective study. Chest 1999; 116: 1168-1174.
15. Xaubt A, Agusti C, Luburich P, Roca J, Monton C, Ayuso MC et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 431-436.
16. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy induced pulmonary injury. Current Opin Oncol 2001; 13: 242-248.
17. Shirner M, Hoffman J, Menard A. Anti-angiogenic chemotherapeutic agents: characterization in comparison to their tumour growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998; 4: 1331-1336.
18. Burger RM, Pesach J, Horwitc SB. Activated bleomycin: A transient complex of drug, iron and oxygen that degrades DNA. J Biol Chem 1981; 256: 11636-11644.
19. Umezawa H, Takeuchi T, Hosi S, Sona T, Ishizuka M. Studies on the mechanism of antitumour effect of bleomycin in squamous cell carcinoma. J Antibiot 1972; 25: 409-420.
20. Onuma T, Holland JF, Masuda H, Waligunda JA, Goldberg GA. Micro-biological assay of bleomycin: inactivation, tissue distribution and clearance. Cancer 1974; 33: 1230-1238.
21. Adamson IY, Bowden DH. The pathogenesis of bleomycin induced pulmonary fibrosis in mice. Am J Pathol 1974; 77: 185-197.
22. Scheule RK, Perkins RC, Hamilton R, Holian A. Bleomycin stimulation of cytokine secretion by the human alveolar macrophage. Am J Physiol 1992; 262: L386-L391.
23. Moseley PL, Shasby DM, Brady M, Hunninghake GW. Lung parenchymal injury induced by bleomycin. Am Rev Respir Dis 1984; 130: 1082-1086.
24. Moseley PL, Hemken C, Hunninghake GW. Augmentation of fibroblast proliferation by bleomycin. J Clin Invest 1986; 78: 1150-1154.
25. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor-β on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48: 959-966.
26. Gurujeyalakshmi G, Wang Y, Giri SN. Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor (NF-β) in mice. J Pharmacol Exp Therap 2000; 293: 82-90.
27. White DA, Stover DE. Severe bleomycin induced pneumonitis: clinical features and response to corticosteroids. Chest 1984; 86: 723-728.
28. Tryka AF, Skornik WA, Godleski JJ, Brain JD. Potentiation of bleomycin induced lung injury by exposure to 70% oxygen. Morphologic assessment. Am Rev Respir Dis 1982; 126: 1074-1076.
29. Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998; 78: 1061-1066.
30. Takita T, Ogino T. Peplomycin and liplomycin, new analogues of bleomycin. Biomed Pharmacother 1987; 41: 219-226.
31. Doll DC, Weiss RB, Issell BF. Mitomycin: ten years after approval for marketing. J Clin Oncol 1985; 3: 276-286.
32. Watanabe I, Yokobayashi T, Nakajima T, Mizutani H, Ohashi Y. Peplomycin induced pneumonitis resulting in death. J Maxillofac Surg 1984; 12: 114-117.
33. Hankins DG, Sanders S, Macdonald FM, Drage CW. Pulmonary toxicity recurring after a six week course of busulfan therapy and after subsequent therapy with uracil mustard. Chest 1978; 73: 415-416.
34. Case records of the Massachusetts General Hospital, weekly clinico pathologic excercises. Case 25-1997. A 60 year old man with pulmonary infiltrates after bone marrow transplantation. N Engl J Med 1997; 337: 480-489.
35. Rosenow E. Drug induced pulmonary disease. Dis Mon 1994; 150: 253-310
36. Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol 1982; 9: 34-51.
37. Segura A, Yuste A, Cercos A, Lopez-Tendero P, Girones R, Perez-Fidalgo JA et al. Pulmonary fibrosis induced by cyclophosphamide. Ann Pharmacother 2001; 35: 894-897.
38. Stentoft J. Progressive pulmonary fibrosis complicating cyclophosphamide therapy. Acta Med Scand 1987; 221: 403-407.
39. Crestani B, Jaccard A, Israel-Biet D, Coudere LJ, Frija J, Clauvel JP. Chlorambucil associated pneumonitis. Chest 1994; 105: 634-636.
40. Goucher G, Rowland V, Hawkins J. Melphalan induced pulmonary interstitial fibrosis. Chest 1980; 77: 805-816.
41. Israel-Biet D, Labrune S, Huchon GJ. Drug induced lung disease: 1990 review. Eure Respir J 1991; 4: 465-478.
42. Sostman HD. Methotrexate induced pneumonitis. Medicine 1976; 62: 608.
43. Vandenberg TA, Pritchard KI, Eisenhauer EA, Trudeau ME, Norris BD, Lopez P et al. Phase II study of weekly edatrexate as first line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1993; 11: 1241-1244.
44. Konits PH, Aisner J, Sutherland JC, Wiernik PH. Possible pulmonary toxicity secondary to vinblastine. Cancer 1982; 50: 2771-2774.
45. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy related lung fibrosis enhanced by Tamoxifen. J Natl Cancer Inst 1996; 88: 918-922.
46. MacCaffery JA, Scher HI. Interstitial pneumonitis following bicalutamide treatment for prostate cancer. J Urol 1998; 160: 131.
47. Seigneur J, Trechot PE, Hubert J, Lamy P. Pulmonary complications of hormone treatment in prostate carcinoma. Chest 1988; 93: 1106.
48. Kowey PR, Marinchak RA, Rials SJ, Filart RA. Intravenous amiodarone. J Am Coll Cardiol 1997; 29: 1190-1198.
49. Lee KL, Tai YT. Long term low dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety. Clin Cardiol 1997; 20: 372-377.
50. Bolt MW, Card JW, Brian JF, Massey TE. Disruption of mitochondrial function and cellular ATP levels by amiodraone and N-desethylamiodarone in initiation of amiodarone induced pulmonary cytotoxicity. J Pharmacol Exp Therap 2001; 298: 1280-1289.
51. Bero CJ, Rihn TL. Possible association of pulmonary fibrosis with mexiletine. DICP 1991; 25: 1329-1331.
52. Woosley RL, Drayer DE, Reidenbrg MM, Nies AS, Carr K, Oates JA. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978; 298: 1157-1159.
53. Barnett R, Israel HL, Scott R, Fish JE, Peters SP. Pulmonary fibrosis in a patient treated with bumetanide: clinical improvement associated with transition from a granulocytic to lymphocytic alveolitis. Respir Med 1990; 84: 71-75.
54. D'Arcy PF. Drug interactions and reactions update: Nitrofurantoin. Drug Intell Clin Pharm 1985; 19: 540-547.
55. Aronchick JM, Gefter WB. Drug induced pulmonary disease: an update. J Thorac Imaging 1991; 6: 19-29.
56. Evans RB, Ettensohn DB, Fawaz-Estrup F, Lally EV, Kaplan SR. Gold lung: recent developments in pathogenesis, diagnosis and therapy. Semin Arthritis Rheum 1987; 16: 196-205.
57. Sossai P, Cappellato MG, Stefani S. Can a drug induced pulmonary hypersensitivity reaction be dose dependent? A case with mesalamine. Mt Sinai J Med 2001; 68: 380-395.
58. Morice A, Atherton A, Gleeson F, Stewart S. Pulmonary fibrosis associated with nabumetone. Postgrad Med J 1991; 67: 1021-1022.
59. Polman AJ, van der Werf TS, Teibosch AT, Zijlstra JG. Early onset phenytoin toxicity mimicking a reno-pulmonary syndrome. Eur Respir J 1998; 11: 501-503.
60. McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988; 148: 2231-2236.
61. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson's disease with a long acting ergot derivative, cabergoline. Eur Respir J 1992; 5: 263-265.